In a woman with a pessary in place for pelvic organ prolapse, is oral fluconazole or vaginal azole therapy the preferred treatment for a vaginal yeast infection?

Treatment of Vaginal Yeast Infection with Pessary in Place

For a woman with a pessary in place, oral fluconazole 150 mg single dose is the preferred treatment for vaginal yeast infection, as it avoids mechanical interference with the pessary and provides equivalent efficacy to vaginal therapy. 12

Rationale for Oral Therapy

The 2021 CDC STI Treatment Guidelines establish that both oral fluconazole (150 mg single dose) and intravaginal azole therapies are equally effective for uncomplicated vulvovaginal candidiasis 1. However, the presence of a pessary creates a unique clinical scenario where vaginal administration becomes problematic:

• Mechanical considerations: Vaginal creams, suppositories, or pessaries would need to be inserted around or near the pessary device, potentially displacing it or reducing drug contact with vaginal mucosa
• Patient convenience: Oral therapy eliminates concerns about proper vaginal application with a pessary in situ
• Equivalent efficacy: Clinical cure rates are comparable between routes (oral 75-83% vs vaginal 77-80% at short-term follow-up) 3

Evidence Supporting Oral Fluconazole

The FDA-approved fluconazole regimen is straightforward: a single 150 mg oral tablet 2. This approach has demonstrated:

• Clinical cure rates of 94% at 14-day evaluation 4
• Mycological cure rates of 77% at short-term follow-up 4
• Slightly superior mycological cure compared to intravaginal treatment (OR 1.24,95% CI 1.03-1.50) 3
• Patient preference: Women consistently prefer oral over vaginal administration 35

Important Caveats

When to Avoid Oral Fluconazole

Do not use oral fluconazole if the patient:

• Takes quinidine, erythromycin, or pimozide (contraindicated) 2
• Has significant liver or kidney disease 2
• Has cardiac arrhythmias, hypokalemia, or advanced heart failure (risk of QT prolongation) 2
• Is pregnant or breastfeeding 2

Side Effect Profile Differences

While overall adverse event rates are similar (oral 27% vs vaginal 17%), the type of side effects differs 23:

• Oral therapy: Gastrointestinal symptoms, headaches (systemic effects)
• Vaginal therapy: Local irritation, burning (which would be particularly problematic with a pessary in place)

Alternative Considerations

If oral fluconazole is contraindicated or fails:

• Remove the pessary temporarily (if clinically feasible) to allow proper vaginal azole application for 3-7 days 1
• Consider boric acid 600 mg vaginal suppositories for fluconazole-resistant cases (85.7% mycological cure rate), though this still requires pessary management 6
• For recurrent infections (≥4 episodes/year), long-term suppressive fluconazole may be needed after acute treatment 7

Clinical Pitfall to Avoid

Do not assume all vaginal symptoms are yeast infections. Less than 50% of patients clinically diagnosed with VVC actually have confirmed infection 1. With a pessary in place, symptoms could represent:

• Bacterial vaginosis
• Pessary-related irritation or erosion
• Atrophic vaginitis
• Trichomoniasis

Obtain microscopy or culture confirmation before treating, especially in this population where pessary-related complications can mimic infection 1.

Practical Algorithm

1. Confirm diagnosis: Obtain vaginal swab for microscopy/culture (can be done with pessary in place)
2. Screen contraindications: Review medication list and cardiac/hepatic history
3. Prescribe oral fluconazole 150 mg as single dose if no contraindications
4. Follow-up: If symptoms persist beyond 7 days, consider culture results and alternative diagnoses
5. Recurrent cases: Evaluate for complicated VVC and consider maintenance therapy

The presence of a pessary makes oral therapy the clear practical choice, avoiding the mechanical complications of vaginal administration while maintaining therapeutic equivalence.